Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on November 18, 2025. The filing discloses the appointment of three new Executive Officers and the terms of their employment agreements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
- Base Salary: $225,000 annually per executive.
- Target Bonus: 35% of base salary (performance-based).
- Severance (Without Cause/Good Reason): $225,000 lump sum plus nine months of COBRA benefits.
Material Changes
On November 18, 2025, the Company entered into employment agreements with the following individuals:
- Frederick E. Pierce: Appointed Chief Executive Officer.
- Dr. Barbara Hibner: Appointed Chief Scientific Officer.
- Peter Marschel: Appointed Chief Business Officer.
The filing does not provide comparative data against prior periods as it is a disclosure of new contractual terms rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of general business risks. The primary contingency noted is the requirement for executives to deliver a formal release of all claims as a condition for receiving severance payments or post-employment benefits.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics Inc.
- Review the attached Exhibits 10.1, 10.2, and 10.3 for the full legal definitions of "cause" and "good reason."
- Confirm the performance objectives for the 35% target bonus, which are to be determined by the Compensation Committee.
- Check subsequent filings for any updates to the company's cash position required to fund these new executive salaries and potential severance obligations.